Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 20Thoracic 9Gastrointestinal 8Lymphoid 7Other solid neoplasm 6CNS 6Gynecologic 5Head & Neck 4Other hematologic neoplasm 3Tumor-Agnostic 1Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

3rd Line GIST 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NVP-BKM120 × Sarcoma × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡